A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Trial Profile

A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Idasanutlin (Primary)
  • Indications Polycythaemia vera
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 15 Jun 2018 Planned End Date changed from 20 Mar 2021 to 30 Mar 2021.
    • 15 Jun 2018 Planned primary completion date changed from 10 Apr 2019 to 8 Nov 2019.
    • 02 Mar 2018 Planned End Date changed from 30 Sep 2020 to 20 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top